GlaxoSmithKline completed the acquisition of Sierra Oncology for $1.9bn.

GlaxoSmithKline, a science-led global healthcare company, completed the acquisition of Sierra Oncology, a late-stage clinical drug development biopharmaceutical company, for $1.9bn. "Sierra Oncology complements our commercial and medical expertise in haematology. Momelotinib offers a differentiated treatment option that could address the significant unmet medical needs of myelofibrosis patients with anaemia, the major reason patients discontinue treatment. With this proposed acquisition, we have the opportunity to potentially bring meaningful new benefits to patients and further strengthen our portfolio of specialty medicines," Luke Miels, GSK CCO.